Ipca Laboratories share price falls 2.01% during today's session

Ipca Laboratories' stock declined by 2.01% to Rs 1,361.80 in today's session, according to Moneycontrol data. The movement reflects a notable shift in investor activity. Ipca Laboratories is part of the NIFTY MIDCAP 150 index.

Financial Performance:

Ipca Laboratories' financial performance shows consistent revenue and fluctuating net profit figures over the recent quarters and years. The details are as follows:

Quarterly Performance:

• March 2025: Revenue stood at Rs 2,246.69 Crores, a marginal increase from Rs 2,245.37 Crores in December 2024. Net profit significantly decreased to Rs 65.78 Crores from Rs 277.33 Crores in the previous quarter. EPS also declined to Rs 2.67 from Rs 9.78 in December 2024.


• September 2024: The company recorded revenue of Rs 2,354.90 Crores and a net profit of Rs 245.44 Crores.


• June 2024: Revenue was Rs 2,092.63 Crores with a net profit of Rs 198.98 Crores.


• March 2024: Revenue was Rs 2,033.01 Crores and a net profit of Rs 2.91 Crores.

• March 2025: Revenue increased to Rs 8,939.59 Crores, up from Rs 7,705.04 Crores in March 2024. Net profit also rose to Rs 787.53 Crores from Rs 529.21 Crores in the previous year. EPS stood at Rs 29.08, compared to Rs 25.82 in March 2024.


• March 2024: Revenue was Rs 7,705.04 Crores and a net profit of Rs 529.21 Crores.


• March 2023: Revenue was Rs 6,244.32 Crores and a net profit of Rs 491.93 Crores.


• March 2022: Revenue was Rs 5,829.79 Crores and a net profit of Rs 910.95 Crores.


• March 2021: Revenue was Rs 5,419.99 Crores and a net profit of Rs 1,148.84 Crores.

Here’s a summary of Ipca Laboratories' consolidated financials over the past five years:

The company's cash flow from operating activities has shown fluctuations. In March 2025, it stood at Rs 1,321 Crores, compared to Rs 944 Crores in March 2024.